Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.
Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley JF, Gorin NC, Szer J, Bradstock K, Buzyn A, Clark P, Borkett K, Gratwohl A; European Group for Blood and Marrow Transplantation. Schmitz N, et al. Among authors: bradstock k. Blood. 2002 Aug 1;100(3):761-7. doi: 10.1182/blood-2001-12-0304. Blood. 2002. PMID: 12130483 Free article. Clinical Trial.
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.
Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D. Thomas X, et al. Among authors: bradstock k. J Clin Oncol. 2004 Oct 15;22(20):4075-86. doi: 10.1200/JCO.2004.10.050. Epub 2004 Sep 7. J Clin Oncol. 2004. PMID: 15353542 Clinical Trial.
Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.
Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P. Raj K, et al. Among authors: bradstock k. Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18. Biol Blood Marrow Transplant. 2014. PMID: 24650678 Free PMC article.
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Among authors: bradstock k. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes T. Branford S, et al. Among authors: bradstock k. Blood. 2004 Nov 1;104(9):2926-32. doi: 10.1182/blood-2004-03-1134. Epub 2004 Jul 15. Blood. 2004. PMID: 15256429 Free article.
Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study.
Kalff A, Kennedy N, Smiley A, Prince HM, Roberts AW, Bradstock K, De Abreu Lourenço R, Frampton C, Spencer A. Kalff A, et al. Among authors: bradstock k. Lancet Haematol. 2014 Dec;1(3):e112-9. doi: 10.1016/S2352-3026(14)00022-2. Epub 2014 Dec 1. Lancet Haematol. 2014. PMID: 27029229
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui CH, Prosser I, Lewis ID, Bradstock K, Seymour JF; Australasian Leukaemia and Lymphoma Group. Hapgood G, et al. Among authors: bradstock k. Leuk Lymphoma. 2019 Apr;60(4):904-911. doi: 10.1080/10428194.2018.1516873. Epub 2018 Dec 14. Leuk Lymphoma. 2019. PMID: 30547695 Clinical Trial.
255 results